Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder.  For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

Financial Info
: Financials

Financials

v3.8.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 19,253 $ 25,496
Prepaid expenses and other 1,429 947
Total current assets 20,682 26,443
Property and equipment, net 78 91
Restricted cash 89 89
Intangible asset 120 120
Security deposits 11 11
Total assets 20,980 26,754
Current liabilities:    
Accounts payable 1,264 1,296
Accrued expenses 1,100 830
Total current liabilities 2,364 2,126
Deferred rent payable 5 12
Total liabilities 2,369 2,138
Stockholders' equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized, none issued or outstanding
Common stock, $0.001 par value; 150,000,000 shares authorized; 8,010,790 and 7,830,040 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively 8 8
Additional paid in capital 187,914 186,983
Accumulated deficit (169,298) (162,363)
Accumulated other comprehensive loss (13) (12)
Total stockholders' equity 18,611 24,616
Total liabilities and stockholders' equity $ 20,980 $ 26,754
v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
COSTS AND EXPENSES:    
Research and development $ 5,170 $ 2,994
General and administrative 1,818 2,097
Total costs and expenses 6,988 5,091
Operating loss (6,988) (5,091)
Interest income, net 53 27
NET LOSS $ (6,935) $ (5,064)
Net loss per common share, basic and diluted (in dollars per share) $ (0.88) $ (1.27)
Weighted average common shares outstanding, basic and diluted (in shares) 7,850,298 3,985,529
v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (6,935) $ (5,064)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 15 24
Stock-based compensation 399 567
Changes in operating assets and liabilities:    
Prepaid expenses and other (481) 10
Accounts payable (32) (31)
Accrued expenses and deferred rent 263 (300)
Net cash used in operating activities (6,771) (4,794)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of furniture and fixtures (2)
Maturities of marketable securities 4,694
Net cash (used) provided by investing activities (2) 4,694
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds, net of expenses of $45 and $34, respectively from sale of common stock 532 1,102
Net cash provided by financing activities 532 1,102
Effect of currency rate change on cash (2)
Net (decrease) increase in cash, cash equivalents and restricted cash (6,243) 1,002
Cash, cash equivalents and restricted cash beginning of the period 25,585 19,030
Cash, cash equivalents and restricted cash end of period 19,342 20,032
Non-cash financing activities:    
Issuance of common stock under employee benefit plan $ 10